Bharat Biotech concludes Final Analysis for COVAXIN®, claims 77.8 pc efficacy from phase-3 clinical trials

Hyderabad, Bharat Biotech, a global leader in vaccine development and innovation, announced today safety and efficacy analysis data from Phase III clinical trials of COVAXIN®, a whole virion inactivated vaccine against SARS-CoV2, was developed in partnership with ICMR and NIV Pune.

The vaccine maker claimed that the efficacy analysis demonstrates COVAXIN® to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.

It said Efficacy analysis demonstrates COVAXIN® to be 93.4% effective against severe symptomatic

COVID-19 and Safety analysis demonstrates adverse events reported were similar to placebo, with 12% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling

The biotechnology company said Efficacy data demonstrates 63.6% protection against asymptomatic COVID-19 and Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant.

Bharat Biotech in a statement said Phase 3 clinical trials of COVAXIN® was an event driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the 2nd dose, conducted at 25 sites across India. COVAXIN® is formulated with a novel Algel+IMDG adjuvant. IMDG is a TLR7/8 agonist known to induce memory T cell responses along with strong neutralizing antibodies.

It said the activation of cell mediated immune responses is especially valuable in a multi epitope vaccine such as COVAXIN®, where immune protection can be achieved from S, RBD and N proteins alike. IMDG was developed under partnership between Virovax and NIAID, National Institutes of Health USA, the Company added.

COVAXIN® was well tolerated and the Data Safety Monitoring Board has not reported any safety concerns related to the vaccine. The overall rate of adverse events observed in COVAXIN® was lower than that seen in otherCovid-19 vaccines. The safety profile of COVAXIN® is now well established based on inactivated vaccines technology, and in large part due to the extensive 20-year safety track record of Bharat Biotech’s vero cell manufacturing platform.

Furthermore, Bharat Biotech has so far not sought indemnity for COVAXIN® from the Governments.

No licensed SARS-CoV-2 vaccine has reported efficacy against asymptomatic infection in a randomised controlled trial, based on qPCR testing.

COVAXIN® is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission, the company added.

 

(Agencies)

Western Ghats Deforestation Threatens Lives & Livelihoods

Deforestation in the Western Ghats threatens biodiversity, rainfall patterns, water security and livelihoods. Pump storage and infrastructure projects raise serious ecological concerns.

B K Singh   |  10 hours ago

Architects of a Healthy Bloom: Re-engineering India’s Human Capital Infrastructure

Discover how India can transform its human capital through maternal health, early childhood nutrition, teacher reforms, mother-tongue education and decentralised learning.

K. N. Laxminarayan   |  11 hours ago

A New Yalta or a Fractured Order?

The Trump-Xi-Putin summit raises questions about a new world order, shifting global power, Gulf security, Iran tensions and the future of international peace.

DINESH DUBEY   |  11 hours ago

Islamophobia & the Changing Face of Democratic Politics

Rising electoral victories of Muslim candidates in the US and UK highlight how democratic participation, equal citizenship and inclusive politics can challenge Islamophobia.

Dr. Khwaja Iftikhar Ahmed   |  1 day, 8 hours ago

“When Reason Fails, Books Are Torn Apart”

Why Such Disdain for Books? From Sonia Gandhi’s autobiography to Nalanda’s destruction, explore how book burning and ideological intolerance threaten freedom of expression, knowledge and democracy.

Dr Niraj Krishna   |  1 day, 10 hours ago

The Roar of the Tiger and the Well-being of Society

Discover how tiger and big cat conservation protects forests, rivers, biodiversity and climate resilience, while supporting communities and human survival.

Kumar Krishnan   |  1 day, 10 hours ago

Comments

YOU MIGHT ALSO LIKE

View More

By Dr. Khwaja Iftikhar Ahmed   |   1 day, 8 hours ago
Islamophobia & the Changing Face of Democratic Politics
By Dr Niraj Krishna   |   1 day, 10 hours ago
“When Reason Fails, Books Are Torn Apart”
By Khalid Rasool   |   2 days, 10 hours ago
A Quota Decided in Delhi, Questions Raised in Kashmir